Compare KEN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | CRSP |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 2014 | 2016 |
| Metric | KEN | CRSP |
|---|---|---|
| Price | $81.91 | $57.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $70.29 |
| AVG Volume (30 Days) | 18.4K | ★ 1.4M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | N/A | $807.72 |
| Revenue Next Year | N/A | $172.52 |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $29.60 | $33.03 |
| 52 Week High | $89.89 | $78.48 |
| Indicator | KEN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 65.20 |
| Support Level | $78.28 | $51.64 |
| Resistance Level | $86.05 | $60.63 |
| Average True Range (ATR) | 2.24 | 2.44 |
| MACD | -0.44 | 1.13 |
| Stochastic Oscillator | 23.20 | 89.02 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.